Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tinostamustine

Phase 1Small molecule

MMundipharma Research Limited

Tinostamustine is one of 71 small molecule programs targeting Melanoma. It is currently in Phase 1.

2

Indications

6

Total Trials

1

Active Trials

70

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

GlioblastomaActive, not recruiting

MelanomaPhase 1

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Bempegaldesleukin

NNektar Therapeutics

Interferon-Gamma

SSPP Pharmaclon Ltd.

GSK2118436

Anti-PD1

IBI308

Innovent Biologics (Suzhou) Co. Ltd.

Zelboraf

CConrado Roberto Hoffmann Filho

Intron a

Opdualag

Bristol-Myers Squibb

BCD-201

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalRecruiting

Glioblastoma

NCT03970447

Clinical

Trials by Indication[1]

Glioblastoma3 trials

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03452930·5 enrolled

Study of Tinostamustine for Adjuvant Treatment of Glioblastoma

Completed·MMundipharma Research Limited·Phase 1·NCT05432375·10 enrolled

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

Recruiting·GGlobal Coalition for Adaptive Research·Preclinical·NCT03970447·2,250 enrolled

Conditioning1 trial

Tinostamustine Conditioning and Autologous Stem Cell

Terminated·MMundipharma-EDO GmbH·Phase 1/2·NCT03687125·6 enrolled

Melanoma1 trial

Tinostamustine and Nivolumab in Advanced Melanoma

Unknown status·MMarkus Joerger·Phase 1·NCT03903458·21 enrolled

Hematologic Malignancies1 trial

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed·MMundipharma Research Limited·Phase 1·NCT02576496·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tinostamustine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tinostamustine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tinostamustine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mundipharma Research Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMundipharma Research Limited

Related News